Meag Munich Ergo’s Bio-Techne TECH Stock Holding History

Meag Munich Ergo’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,284	Closed	-$482K	–	311
2021 Q2	$482K	Buy	+4,284	New	+$451K	0.05%	266

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Meag Munich Ergo's TECH Position: Q3 2021 in Review

Meag Munich Ergo sold out of Bio-Techne (TECH) in Q3 2021, closing a stake of 4,284 shares — an estimated $482K sold.

Meag Munich Ergo first reported a position in TECH in Q2 2021 and held it in 1 quarter. The position peaked at $482K in Q2 2021. 565 funds tracked by Wall St. Rank hold TECH as of Q3 2021.

Meag Munich Ergo reported no remaining Bio-Techne position as of Q3 2021 after selling out during the quarter.
Meag Munich Ergo sold 4,284 Bio-Techne shares in Q3 2021, an estimated $482K.
Meag Munich Ergo first reported a position in Bio-Techne in Q2 2021 and held it in 1 quarter.
Meag Munich Ergo's Bio-Techne position peaked at $482K in Q2 2021.
565 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2021.

Based on Meag Munich Ergo's 13F filing for Q3 2021, filed 13 Oct 2021.